Last reviewed · How we verify

Apotex Inc. — Portfolio Competitive Intelligence Brief

Apotex Inc. pipeline: 0 marketed, 0 filed, 4 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 4 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Imiquimod Vehicle Imiquimod Vehicle phase 3 Toll-like receptor agonist TLR7/TLR8 Dermatology/Immunology
Adara 5% Cream US Adara 5% Cream US phase 3 Retinoid (third-generation) Retinoic acid receptors (RARs) Dermatology
Imiquimod 5%: manufactured by Apotex Imiquimod 5%: manufactured by Apotex phase 3 TLR7 agonist TLR7 (Toll-like receptor 7) Dermatology, Oncology, Immunology
Adara 5% Cream Canada Adara 5% Cream Canada phase 3 Topical corticosteroid Glucocorticoid receptor Dermatology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Galderma R&D · 2 shared drug classes
  2. Actavis Inc. · 1 shared drug class
  3. Astion Pharma A/S · 1 shared drug class
  4. Aleor Dermaceuticals Limited · 1 shared drug class
  5. All India Institute of Medical Sciences, Bhubaneswar · 1 shared drug class
  6. Astellas Pharma Inc · 1 shared drug class
  7. Al-Azhar University · 1 shared drug class
  8. Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Apotex Inc.:

Cite this brief

Drug Landscape (2026). Apotex Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/apotex-inc. Accessed 2026-05-15.

Related